Ablation of Nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus

Journal of Virology

Volumn 88, Issue 4, 2014, Pages 2195-2204

  Liu, Yu Ping ^a   Russell, Samuel P ^a,b   Ayala Breton, Camilo ^a   Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; HUMANS; IMMUNOBLOTTING; MEASLES VIRUS; RECEPTORS, CELL SURFACE; VERO CELLS; VESICULOVIRUS; VIRUS SHEDDING;

EID: 84893453627     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02628-13     Document Type: Article

References (39)

1. Lech PJ, Russell SJ. 2010. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev. Vaccines 9:1275-1302. http://dx.doi.org/10.1586/erv.10.124.
2. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. 2004. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103:1641-1646. http://dx.doi.org/10.1182/blood-2003-07-2233.
3. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. 2002. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 8:527-531. http://dx.doi.org/10.1038/nm0502-527.
4. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ, Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. 2010. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70:875-882. http://dx.doi.org/10.1158/0008-5472.CAN-09-2762.
5. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. 2002. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62:4656-4662.
6. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. 2003. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63:2462-2469.
7. Ayala-Breton C, Suksanpaisan L, Mader EK, Russell SJ, Peng KW. 2013. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. Mol. Ther. 51:1930-1937. http://dx.doi.org/10.1038/mt.2013.164.
8. Mühlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB, Jr, Cichutek K, von Messling V, Lopez M, Cattaneo R. 2011. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480:530-533. http://dx.doi.org/10.1038/nature10639.
9. Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, Tsao MS, Richardson CD. 2011. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 7:e1002240. http://dx.doi.org/10.1371/journal.ppat.1002240.
10. Noyce RS, Richardson CD. 2012. Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol. 20:429-439. http://dx.doi.org/10.1016/j.tim.2012.05.006.
11. Hsu EC, Sarangi F, Iorio C, Sidhu MS, Udem SA, Dillehay DL, Xu W, Rota PA, Bellini WJ, Richardson CD. 1998. A single amino acid change in the hemagglutinin protein of measles virus determines its ability to bind CD46 and reveals another receptor on marmoset B cells. J. Virol. 72:2905-2916.
12. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. 2004. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM-or CD46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol. 78:302-313. http://dx.doi.org/10.1128/JVI.78.1.302-313.2004.
13. Coughlin MM, Bellini WJ, Rota PA. 2013. Contribution of dendritic cells to measles virus induced immunosuppression. Rev. Med. Virol. 23:126-138. http://dx.doi.org/10.1002/rmv.1735.
14. Kerdiles YM, Sellin CI, Druelle J, Horvat B. 2006. Immunosuppression caused by measles virus: role of viral proteins. Rev. Med. Virol. 16:49-63. http://dx.doi.org/10.1002/rmv.486.
15. Leonard VH, Hodge G, Reyes-Del Valle J, McChesney MB, Cattaneo R. 2010. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J. Virol. 84:3413-3420. http://dx.doi.org/10.1128/JVI.02304-09.
16. Leonard VH, Sinn PL, Hodge G, Miest T, Devaux P, Oezguen N, Braun W, McCray PB, Jr, McChesney MB, Cattaneo R. 2008. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J. Clin. Invest. 118: 2448-2458.
17. Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, Hayakawa T, Cattaneo R, Russell SJ. 2004. Antibody-targeted cell fusion. Nat. Biotechnol. 22:331-336. http://dx.doi.org/10.1038/nbt942.
18. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL, Russell SJ. 2001. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther. 8:1456-1463. http://dx.doi.org/10.1038/sj.gt.3301552.
19. Lawson ND, Stillman EA, Whitt MA, Rose JK. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U.S.A. 92:4477-4481. http://dx.doi.org/10.1073/pnas.92.10.4477.
20. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. 2012. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum. Gene Ther. 23:484-491. http://dx.doi.org/10.1089/hum.2011.146.
21. Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, Blanco MC, Carlson SK, Russell SJ, Peng KW. 2010. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum. Gene Ther. 21:451-462. http://dx.doi.org/10.1089/hum.2009.111.
22. Harcourt JL, Caidi H, Anderson LJ, Haynes LM. 2011. Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection. J. Virol. Methods 174:144-149. http://dx.doi.org/10.1016/j.jviromet.2011.03.027.
23. Geys J, Coenegrachts L, Vercammen J, Engelborghs Y, Nemmar A, Nemery B, Hoet PH. 2006. In vitro study of the pulmonary translocation of nanoparticles: a preliminary study. Toxicol. Lett. 160:218-226. http://dx.doi.org/10.1016/j.toxlet.2005.07.005.
24. Sinn PL, Williams G, Vongpunsawad S, Cattaneo R, McCray PB, Jr. 2002. Measles virus preferentially transduces the basolateral surface of well-differentiated human airway epithelia. J. Virol. 76:2403-2409. http://dx.doi.org/10.1128/jvi.76.5.2403-2409.2002.
25. Oglesby TJ, Allen CJ, Liszewski MK, White DJ, Atkinson JP. 1992. Membrane cofactor protein (CD46) protects cells from complementmediated attack by an intrinsic mechanism. J. Exp. Med. 175:1547-1551. http://dx.doi.org/10.1084/jem.175.6.1547.
26. Anderson BD, Nakamura T, Russell SJ, Peng KW. 2004. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64:4919-4926. http://dx.doi.org/10.1158/0008-5472.CAN-04-0884.
27. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. 2003. Obstacles to cancer immunotherapy: expression of membrane complement regula-tory proteins (mCRPs) in tumors. Mol. Immunol. 40:109-123. http://dx.doi.org/10.1016/S0161-5890(03)00112-3.
28. Loveland BE, Johnstone RW, Russell SM, Thorley BR, McKenzie IF. 1993. Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. Transpl. Immunol. 1:101-108. http://dx.doi.org/10.1016/0966-3274(93) 90002-P.
29. Mamidi S, Cinci M, Hasmann M, Fehring V, Kirschfink M. 2013. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol. Oncol. 7:580-594. http://dx.doi.org/10.1016/j.molonc.2013.02.011.
30. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, Peng KW. 2006. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp. Hematol. 34:713-720. http://dx.doi.org/10.1016/j.exphem.2006.03.002.
31. Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R. 2007. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol. Cancer Res. 5:823-832. http://dx.doi.org/10.1158/1541-7786.MCR-06-0352.
32. Hashiguchi T, Ose T, Kubota M, Maita N, Kamishikiryo J, Maenaka K, Yanagi Y. 2011. Structure of the measles virus hemagglutinin bound to its cellular receptor SLAM. Nat. Struct. Mol. Biol. 18:135-141. http://dx.doi.org/10.1038/nsmb.1969.
33. Santiago C, Celma ML, Stehle T, Casasnovas JM. 2010. Structure of the measles virus hemagglutinin bound to the CD46 receptor. Nat. Struct. Mol. Biol. 17:124-129. http://dx.doi.org/10.1038/nsmb.1726.
34. Zhang X, Lu G, Qi J, Li Y, He Y, Xu X, Shi J, Zhang CW, Yan J, Gao GF. 2013. Structure of measles virus hemagglutinin bound to its epithelial receptor nectin-4. Nat. Struct. Mol. Biol. 20:67-72. http://dx.doi.org/10.1038/nsmb.2432.
35. Mateo M, Navaratnarajah CK, Syed S, Cattaneo R. 2013. The measles virus hemagglutinin beta-propeller head beta4-beta5 hydrophobic groove governs functional interactions with nectin-4 and CD46 but not with the signaling lymphocytic activation molecule. J. Virol. 87:9208-9213. http://dx.doi.org/10.1128/JVI.01210-13.
36. Veillette A, Latour S. 2003. The SLAM family of immune-cell receptors. Curr. Opin. Immunol. 15:277-285. http://dx.doi.org/10.1016/S0952-7915 (03)00041-4.
37. Dörig RE, Marcil A, Richardson CD. 1994. CD46, a primate-specific receptor for measles virus. Trends Microbiol. 2:312-318. http://dx.doi.org/10.1016/0966-842X(94)90447-2.
38. Tatsuo H, Ono N, Tanaka K, Yanagi Y. 2000. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406:893-897. http://dx.doi.org/10.1038/35022579.
39. de Vries RD, McQuaid S, van Amerongen G, Yuksel S, Verburgh RJ, Osterhaus AD, Duprex WP, de Swart RL. 2012. Measles immune suppression: lessons from the macaque model. PLoS Pathog. 8:e1002885. http://dx.doi.org/10.1371/journal.ppat.1002885.